Despite a brutal price year, China’s large automakers are in surprisingly good shape. That means the EV price war will continue.

The yen has plummeted against the dollar this year, hurt by increasing doubts among traders about the timing of U.S. interest-rate cuts.

A slumping stock price has tempered Apple’s valuation, making another weak iPhone report less risky.

Credit scores and other factors have a growing impact on borrowing cost.

CVS is getting into the business of making copycat biologic drugs, known as biosimilars, to profit directly from blockbusters going generic.

Around the country, investors are getting jittery about the coming Biden-Trump rematch and peppering financial advisers with questions about what the contest will mean for their portfolios.